INSIGHTS ON PHARMACEUTICAL PRODUCTION

• Process-Economy Simulation Of mAb Capture Step With Protein A Chromatography Resin

  Calculation examples that highlight scenarios where the enhanced capacity and alkaline‑stability of MabSelect PrismA can provide process economic benefits to large‑scale mAb processing.

• Why Choose A Commercial HPAPI Manufacturer For Your Clinical Program?

  Switching from an early-phase CDMO to a commercial-scale manufacturer for your highly potent active pharmaceutical ingredient (HPAPI) projects can be costly and lead to project delays.

• Quick To Clinic™ for Oral Solid Dose

  In as little as 14 weeks from receiving your small molecule API, you can have your Phase I drug product manufactured, labelled, packaged and delivered to the clinic. That’s 1 month faster than most standard timelines, and includes a one-month stability study.

• Automated Foam Control In HyPerforma™ Single-Use Bioreactors Using A Single-Use Foam Probe

  The generation of foam is common in aerobic bioreactor systems. Foaming can cause a range of problems, including increased contamination risks through potential exhaust filter fouling, poor mass transfer, product/cell entrainment, increased shearing from bursting bubbles, and cell death. A foam probe for S.U.B. systems provides a robust solution for foam management.

• Capacity And Performance Of MabSelect™ PrismA Protein A Chromatography Resin

  This application note demonstrates the binding capacity of MabSelect PrismA in comparison with its predecessor products for both polyclonal and monoclonal antibodies.

• How Can Extrusion Benefit Your Pharmaceutical Oral Drug Product?

  Due to its immense adaptability, extrusion has been widely utilized in diverse fields. It is being adopted more recently by the pharmaceutical industry at an unprecedented pace.

• A QbD Approach To Continuous Tablet Manufacture - Utilizing The FT4 Powder Rheometer And The GEA ConsiGma™ Twin Screw High Shear Granulator

  In order to maximize the benefit of continuous processing, and obtain regulatory approval, it is necessary to establish the link between the processing parameters and the product attributes - something that is difficult to achieve due to the insensitivity of many traditional methods for powder and granule testing. This study summarizes initial work between Freeman Technology and GEA which has explored the relationship between granule properties and variation in formulation and processing parameters in a continuous manufacturing environment.

• Recommended Blending Equipment For Nutraceuticals

  Dry blending is an indispensable operation in the manufacture of multivitamins, sports supplements, herbal extracts, meal-replacements, green food powders and other nutraceutical products.

• Achieving Unique Synergies In Antibody Expression

  Shortening timelines to generate more productive, stable and high expressing cell lines is the goal of any cell line development program. This technical poster details the methodologies and clonal variation of combining a cell line development technology with a platform for clonal cell line selection.